The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XXIV.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Dan L, Liu Z, Zhao Z, Ran Y, Zhou J, Li D, Zhou R, Su S, Yin Z

Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database.

Naunyn-Schmiedeberg's archives of pharmacology. 2026;399(9):13661-13676

Maroto JP, Hudes G, Dutcher JP, Logan TF, White CS, Krygowski M, Cincotta M, Shapiro M, Duran I, Berkenblit A

Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(13):1750-6

Duran I, Siu LL, Oza AM, Chung TB, Sturgeon J, Townsley CA, Pond GR, Seymour L, Niroumand M

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus.

European journal of cancer (Oxford, England : 1990). 2006;42(12):1875-80